A detailed history of Geode Capital Management, LLC transactions in Biovie Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 231,656 shares of BIVI stock, worth $641,687. This represents 0.0% of its overall portfolio holdings.

Number of Shares
231,656
Previous 247,106 6.25%
Holding current value
$641,687
Previous $130,000 29.23%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$0.4 - $0.56 $6,180 - $8,652
-15,450 Reduced 6.25%
231,656 $92,000
Q1 2024

May 13, 2024

BUY
$0.53 - $1.89 $31,544 - $112,487
59,517 Added 31.73%
247,106 $130,000
Q4 2023

Feb 13, 2024

BUY
$1.22 - $5.24 $59,993 - $257,677
49,175 Added 35.53%
187,589 $236,000
Q3 2023

Nov 13, 2023

SELL
$2.75 - $5.17 $35,917 - $67,525
-13,061 Reduced 8.62%
138,414 $471,000
Q2 2023

Aug 11, 2023

BUY
$4.09 - $8.29 $127,910 - $259,261
31,274 Added 26.02%
151,475 $652,000
Q1 2023

May 15, 2023

BUY
$4.89 - $10.53 $213,257 - $459,223
43,611 Added 56.94%
120,201 $971,000
Q4 2022

Feb 13, 2023

BUY
$3.86 - $42.0 $143,406 - $1.56 Million
37,152 Added 94.2%
76,590 $595,000
Q2 2022

Aug 12, 2022

BUY
$1.44 - $5.04 $7,273 - $25,457
5,051 Added 14.69%
39,438 $57,000
Q1 2022

May 13, 2022

BUY
$2.74 - $5.65 $16,492 - $34,007
6,019 Added 21.22%
34,387 $162,000
Q4 2021

Feb 11, 2022

BUY
$4.41 - $6.99 $41,520 - $65,810
9,415 Added 49.68%
28,368 $127,000
Q3 2021

Nov 12, 2021

SELL
$6.69 - $16.93 $26,392 - $66,788
-3,945 Reduced 17.23%
18,953 $127,000
Q2 2021

Aug 13, 2021

BUY
$10.57 - $21.61 $17,947 - $36,693
1,698 Added 8.01%
22,898 $388,000
Q1 2021

May 12, 2021

BUY
$14.35 - $44.81 $304,220 - $949,972
21,200 New
21,200 $410,000

Others Institutions Holding BIVI

About BIOVIE INC.


  • Ticker BIVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,165,300
  • Market Cap $83.6M
  • Description
  • BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...
More about BIVI
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.